StockData
Immunocore Holdings plc logo

Immunocore Holdings plc (IMCR) stock

IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/3014% below fair value
$27.81−1.07 (-3.70%)

Close on Nov 17, 2026Market cap $1.43BP/E –Yield 0.00%

Immunocore price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Immunocore's price to sales ratio was 3.8× on Nov 11, 2026, against 5.3× a year earlier. Over the last 5 years it ranged from 0.2× to 72.3×, with a median of 4.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.8×−0.8
2025Dec 31, 20254.6×−0.4
2024Dec 31, 20245.0×−13.9
2023Dec 29, 202318.8×+18.5
2022Dec 30, 20220.3×–

More Immunocore figures

See a number that looks wrong?